Shares in Affymetrix Up 17 Percent; UBS Upgrades Stock | GenomeWeb
NEW YORK (GenomeWeb News) — Shares in Affymetrix were up 17.74 percent, or $4.09, at $26.72 this afternoon after the company yesterday released its third-quarter earnings.
 
Today, investment bank UBS upgraded its rating of Affy shares to ‘Neutral’ from ‘Reduce.’
 
As GenomeWeb News reported yesterday, Affy said that third-quarter revenue increased around 1 percent as last year's profit swung to a loss.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genome-wide transcriptome analysis of brain samples from people with autism spectrum disorder, flounder genome, and more.

Researchers used T-cell transfer therapy to target mutation KRAS, according to the New York Times.

The US Senate has passed the 21st Century Cures Act, which would provide a funding boost at NIH while overhauling FDA policies.

Bloomberg reports that President-elect Donald Trump is considering Jim O'Neill for Food and Drug Administration commissioner.